Back to Browse Journals » ImmunoTargets and Therapy

ImmunoTargets and Therapy


Journal Articles:

- 60 records -

CD8+ memory T-cell inflation renders compromised CD4+ T-cell-dependent CD8+ T-cell immunity via naïve T-cell anergy

Xu A, Freywald A, Xie Y, Li Z, Xiang J

ImmunoTargets and Therapy 2017, 6:39-49

Published Date: 15 June 2017

Phase I clinical trial of sipuleucel-T combined with escalating doses of ipilimumab in progressive metastatic castrate-resistant prostate cancer

Scholz M, Yep S, Chancey M, Kelly C, Chau K, Turner J, Lam R, Drake CG

ImmunoTargets and Therapy 2017, 6:11-16

Published Date: 20 March 2017

First-line treatment of metastatic melanoma: role of nivolumab

Force J, Salama AK

ImmunoTargets and Therapy 2017, 6:1-10

Published Date: 13 February 2017

Prion diseases: immunotargets and therapy

Burchell JT, Panegyres PK

ImmunoTargets and Therapy 2016, 5:57-68

Published Date: 16 June 2016

The role of adipokines in chronic inflammation

Mancuso P

ImmunoTargets and Therapy 2016, 5:47-56

Published Date: 23 May 2016

Immunotherapy for tuberculosis: future prospects

Abate G, Hoft DF

ImmunoTargets and Therapy 2016, 5:37-45

Published Date: 20 April 2016

Current and emerging treatment options in the management of lupus

Jordan N, D’Cruz D

ImmunoTargets and Therapy 2016, 5:9-20

Published Date: 2 March 2016

The role of regulatory T cells in cancer immunology

Whiteside TL

ImmunoTargets and Therapy 2015, 4:159-171

Published Date: 5 August 2015

The hygiene hypothesis: current perspectives and future therapies

Stiemsma LT, Reynolds LA, Turvey SE, Finlay BB

ImmunoTargets and Therapy 2015, 4:143-157

Published Date: 27 July 2015

Novel perspectives on non-canonical inflammasome activation

Diamond CE, Khameneh HJ, Brough D, Mortellaro A

ImmunoTargets and Therapy 2015, 4:131-141

Published Date: 24 July 2015

Anti-ghrelin antibodies in appetite suppression: recent advances in obesity pharmacotherapy

Altabas V, Zjačić-Rotkvić V

ImmunoTargets and Therapy 2015, 4:123-130

Published Date: 9 July 2015

CD28 co-stimulation in T-cell homeostasis: a recent perspective

Beyersdorf N, Kerkau T, Hünig T

ImmunoTargets and Therapy 2015, 4:111-122

Published Date: 28 May 2015

Emerging roles for HMGB1 protein in immunity, inflammation, and cancer

Martinotti S, Patrone M, Ranzato E

ImmunoTargets and Therapy 2015, 4:101-109

Published Date: 26 May 2015

Enhancement of antibody-dependent cell mediated cytotoxicity: a new era in cancer treatment

Rajasekaran N, Chester C, Yonezawa A, Zhao X, Kohrt HE

ImmunoTargets and Therapy 2015, 4:91-100

Published Date: 15 May 2015

Update on use of aldesleukin for treatment of high-risk metastatic melanoma

Amaria RN, Reuben A, Cooper ZA, Wargo JA

ImmunoTargets and Therapy 2015, 4:79-89

Published Date: 7 April 2015

Emerging role of Natural killer cells in oncolytic virotherapy

Bhat R, Rommelaere J

ImmunoTargets and Therapy 2015, 4:65-77

Published Date: 31 March 2015

Management of patients with non-Hodgkin’s lymphoma: focus on adoptive T-cell therapy

Perna SK, Huye LE, Savoldo B

ImmunoTargets and Therapy 2015, 4:55-63

Published Date: 19 March 2015

Development of antibody-based c-Met inhibitors for targeted cancer therapy

Lee D, Sung ES, Ahn JH, An S, Huh J, You WK

ImmunoTargets and Therapy 2015, 4:35-44

Published Date: 9 February 2015

Alzheimer’s disease and immunotherapy: what is wrong with clinical trials?

Kohyama K, Matsumoto Y

ImmunoTargets and Therapy 2015, 4:27-34

Published Date: 8 January 2015

The role of autophagy in microbial infection and immunity

Desai M, Fang R, Sun J

ImmunoTargets and Therapy 2015, 4:13-26

Published Date: 6 January 2015

Antigen-based immunotherapy for autoimmune disease: current status

Hirsch DL, Ponda P

ImmunoTargets and Therapy 2015, 4:1-11

Published Date: 16 December 2014

Therapeutic cancer vaccines and combination immunotherapies involving vaccination

Nguyen T, Urban J, Kalinski P

ImmunoTargets and Therapy 2014, 3:135-150

Published Date: 6 October 2014

Nanocarrier-based immunotherapy in cancer management and research

Singh MS, Bhaskar S

ImmunoTargets and Therapy 2014, 3:121-134

Published Date: 26 June 2014

Hairy cell leukemia – immunotargets and therapies

Basheer F, Bloxham DM, Scott MA, Follows GA

ImmunoTargets and Therapy 2014, 3:107-120

Published Date: 24 June 2014

Clinical potential of apremilast in the treatment of psoriatic arthritis

Cauli A, Porru G, Piga M, Vacca A, Dessole G, Mathieu A

ImmunoTargets and Therapy 2014, 3:91-96

Published Date: 9 June 2014

Emerging options for the treatment of melanoma – focus on ipilimumab

Roddie C, Peggs KS

ImmunoTargets and Therapy 2014, 3:67-78

Published Date: 17 March 2014

Interleukin-17 and type 17 helper T cells in cancer management and research

Llosa NJ, Geis AL, Thiele Orberg E, Housseau F

ImmunoTargets and Therapy 2014, 3:39-54

Published Date: 10 March 2014

B cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292

Arnason JE, Brown JR

ImmunoTargets and Therapy 2014, 3:29-38

Published Date: 24 January 2014

Immunotherapy for the treatment of Alzheimer's disease: amyloid-β or tau, which is the right target?

Castillo-Carranza DL, Guerrero-Muñoz MJ, Kayed R

ImmunoTargets and Therapy 2014, 3:19-28

Published Date: 27 December 2013

Implications of chemokine receptors and inflammatory lipids in cancer

Rolin J, Maghazachi AA

ImmunoTargets and Therapy 2014, 3:9-18

Published Date: 24 December 2013

Therapeutic vaccines in non-small cell lung cancer

Socola F, Scherfenberg N, Raez LE

ImmunoTargets and Therapy 2013, 2:115-124

Published Date: 19 September 2013

Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer's disease

Lambracht-Washington D, Rosenberg RN

ImmunoTargets and Therapy 2013, 2:105-114

Published Date: 12 August 2013

Metastatic renal cell carcinoma: update on epidemiology, genetics, and therapeutic modalities

Graves A, Hessamodini H, Wong G,Lim WH

ImmunoTargets and Therapy 2013, 2:73-90

Published Date: 23 July 2013

Allergen immunotherapy: routes, safety,efficacy, and mode of action

Hochfelder JL, Ponda P

ImmunoTargets and Therapy 2013, 2:61-71

Published Date: 23 July 2013

Immunotargeting in the management of psoriasis

Kaffenberger BH, Kaffenberger TM, Wong HK

ImmunoTargets and Therapy 2013, 2:51-60

Published Date: 1 July 2013

Update on the challenges and recent advances in cancer immunotherapy

Baronzio G, Parmar G, Shubina IZH, Cassutti V, Giuli S, Ballerini M, Kiselevsky M

ImmunoTargets and Therapy 2013, 2:39-49

Published Date: 17 June 2013

The association between Lambert–Eaton myasthenic syndrome and small cell lung carcinoma

Briggs SEW, Gozzard P, Talbot DC

ImmunoTargets and Therapy 2013, 2:31-37

Published Date: 22 May 2013

Update on immunopathogenesis and immunotherapy in multiple sclerosis

Selter RC, Hemmer B

ImmunoTargets and Therapy 2013, 2:21-30

Published Date: 26 April 2013

Cancer testis antigen and immunotherapy

Krishnadas DK, Bai F, Lucas KG

ImmunoTargets and Therapy 2013, 2:11-19

Published Date: 18 April 2013

Immunotherapy in the management of melanoma: current status

Alston D, Brewer JD

ImmunoTargets and Therapy 2013, 2:1-10

Published Date: 26 February 2013

T-cell activation is enhanced by targeting IL-10 cytokine production in toll-like receptor- stimulated macrophages

Walk RM, Elliot ST, Blanco FC, Snyder JA, Jacobi AM, Rose SD, Behlke MA, Salem AK, Vukmanovic S, Sandler AD

ImmunoTargets and Therapy 2012, 1:13-23

Published Date: 23 November 2012

Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer

Srivastava MK, Zhu L, Harris-White M, Huang M, St John M, Lee JM, Salgia R, Cameron RB, Strieter R, Dubinett S, Sharma S

ImmunoTargets and Therapy 2012, 1:7-12

Published Date: 12 October 2012

Cancer as an immune-mediated disease

Shurin MR

ImmunoTargets and Therapy 2012, 1:1-6

Published Date: 14 June 2012